Cerus (CERS) Should Benefit From FDA Revised Zika Guidance - FBR

August 30, 2016 6:49 AM EDT
Get Alerts CERS Hot Sheet
Price: $4.91 +2.08%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 49 | New: 20
Trade CERS Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

FBR Capital analyst, Thomas Yip, reiterated his Outperform rating on shares of Cerus (NASDAQ: CERS) after the FDA issued revised industry guidance last Friday (August 26, 2016) for reducing the risk of Zika virus (ZIKV) transmission. The analyst thinks that the agency's tightening requirements for blood providers in response to a potential ZIKV outbreak are likely to evolve into a higher safety standard for the industry in the long run.

The primary objective of the revised guidance is to safeguard whole blood and individual blood components collected in all U.S. states and U.S. territories against ZIKV in the immediate time frame. However, he thinks the speed of implementation mandated for blood providers signals the FDA's increasing emphasis on safeguarding the U.S. blood supply at the point of collection, could lead to increased INTERCEPT adoption in a longer time horizon.

No change to the price target of $10.00

For an analyst ratings summary and ratings history on Cerus click here. For more ratings news on Cerus click here.

Shares of Cerus closed at $6.90 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, FDA

Add Your Comment